Janet Soul, MD, is working to improve the treatment and outcome of babies who have an interruption in their supply of oxygen and/or blood flow around the time of birth, a condition called hypoxia-ischemia. When babies experience hypoxia-ischemia, they can develop a brain injury that results in serious neurological problems later in life, such as cerebral palsy or learning difficulties. Together with colleagues in the Neonatal Intensive Care Unit at Boston Children’s Hospital, Soul developed a hypothermia protocol to treat these babies in order to prevent or minimize brain damage.
Babies who have experienced hypoxic-ischemic injury can suffer from seizures. Because many existing anti-seizure medicines do not work well for newborns, Soul is leading a clinical trial of a new seizure medicine for them. This study, which is supported by a grant from the National Institutes of Health, is the first randomized trial of a new seizure medicine to be tested in newborns in decades. The scientific research leading up to this clinical trial was also done at Boston Children’s, in the laboratory of neurologist Frances Jensen, MD.